{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T08:51:21Z","timestamp":1781686281728,"version":"3.54.5"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005743","name":"Universit\u00e0 Cattolica del Sacro Cuore","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005743","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacol. Rep"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s43440-026-00847-5","type":"journal-article","created":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T10:18:44Z","timestamp":1774347524000},"page":"891-901","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Analysis of possible baseline and treatment-course factors associated with non-remission in patients with Crohn\u2019s disease treated with ustekinumab: a retrospective real-life analysis"],"prefix":"10.1007","volume":"78","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5767-5541","authenticated-orcid":false,"given":"Antonio","family":"Tursi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"Pellegrino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giammarco","family":"Mocci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Elisei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Scaldaferri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo V.","family":"Savarino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Maconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia","family":"Bodini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4186-7298","authenticated-orcid":false,"given":"Alfredo","family":"Papa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonietta Gerarda","family":"Gravina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,24]]},"reference":[{"key":"847_CR1","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1038\/nm.3895","volume":"21","author":"MWL Teng","year":"2015","unstructured":"Teng MWL, Bowman EP, McElwee JJ, Smyth MJ, Casanova JL, Cooper AM, Cua DJ. IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases. Nat Med. 2015;21:719\u201329.","journal-title":"Nat Med"},{"key":"847_CR2","unstructured":"European Medicines Agency, Stelara EMA. Product information. [Internet]. 2023. Available from: http:\/\/ec.europa.eu\/health\/documents\/community-register\/html\/h494.htm"},{"key":"847_CR3","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.3390\/jcm13051519","volume":"13","author":"G Mocci","year":"2024","unstructured":"Mocci G, Tursi A, Onidi FM, Usai-Satta P, Pes GM, Dore MP. Ustekinumab in the treatment of inflammatory bowel diseases: evolving paradigms. J Clin Med. 2024;13:1519.","journal-title":"J Clin Med"},{"key":"847_CR4","first-page":"160","volume":"11","author":"D Zaghi","year":"2012","unstructured":"Zaghi D, Krueger GG, Callis Duffin K. Ustekinumab: a review in the treatment of plaque psoriasis and psoriatic arthritis. J Drugs Dermatol. 2012;11:160\u20137.","journal-title":"J Drugs Dermatol"},{"key":"847_CR5","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","volume":"375","author":"BG Feagan","year":"2016","unstructured":"Feagan BG, Sandborn WJ, Gasink C, Jacobstein D, Lang Y, Friedman JR, UNITI\u2013IM-UNITI Study Group, et al. Ustekinumab as induction and maintenance therapy for Crohn\u2019s disease. N Engl J Med. 2016;375:1946\u201360.","journal-title":"N Engl J Med"},{"key":"847_CR6","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1056\/NEJMoa1203572","volume":"367","author":"WJ Sandborn","year":"2012","unstructured":"Sandborn WJ, Gasink C, Gao LL, Blank MA, Johanns J, Guzzo C, CERTIFI Study Group, et al. Ustekinumab induction and maintenance therapy in refractory Crohn\u2019s disease. N Engl J Med. 2012;367:1519\u201328.","journal-title":"N Engl J Med"},{"key":"847_CR7","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1093\/ecco-jcc\/jjz080","volume":"13","author":"C Liefferinckx","year":"2019","unstructured":"Liefferinckx C, Verstockt B, Gils A, Noman M, Van Kemseke C, Macken E, Belgian Inflammatory Bowel Disease Research and Development Group [BIRD group], et al. Long-term clinical effectiveness of ustekinumab in patients with Crohn\u2019s disease Who failed biologic therapies: a national cohort study. J Crohns Colitis. 2019;13:1401\u20139.","journal-title":"J Crohns Colitis"},{"key":"847_CR8","doi-asserted-by":"publisher","first-page":"7192","DOI":"10.3390\/jcm13237192","volume":"13","author":"G Mocci","year":"2024","unstructured":"Mocci G, Tursi A, Scaldaferri F, Napolitano D, Pugliese D, Capobianco I, et al. Long-term effectiveness and safety of ustekinumab in Crohn\u2019s disease: results from a large real-life cohort study. J Clin Med. 2024;13:7192.","journal-title":"J Clin Med"},{"key":"847_CR9","doi-asserted-by":"publisher","first-page":"4481","DOI":"10.3748\/wjg.v25.i31.4481","volume":"25","author":"P Hoffmann","year":"2019","unstructured":"Hoffmann P, Krisam J, Wehling C, Kloeters-Plachky P, Leopold Y, Belling N, Gauss A, Ustekinumab. Real-world outcomes and potential predictors of nonresponse in treatment-refractory Crohn\u2019s disease. World J Gastroenterol. 2019;25:4481\u201392.","journal-title":"World J Gastroenterol"},{"key":"847_CR10","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1093\/ecco-jcc\/jjz119","volume":"14","author":"VBC Biemans","year":"2020","unstructured":"Biemans VBC, van der Meulen-de Jong AE, van der Woude CJ, L\u00f6wenberg M, Dijkstra G, Oldenburg B, et al. Ustekinumab for Crohn\u2019s disease: results of the ICC registry, a nationwide prospective observational cohort study. J Crohns Colitis. 2020;14:33\u201345.","journal-title":"J Crohns Colitis"},{"key":"847_CR11","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s00384-023-04359-z","volume":"38","author":"M Esaki","year":"2023","unstructured":"Esaki M, Ihara Y, Tominaga N, Takedomi H, Tsuruoka N, Akutagawa T, et al. Predictive factors of the clinical efficacy of ustekinumab in patients with refractory Crohn\u2019s disease: tertiary centers experience in Japan. Int J Colorectal Dis. 2023;38:57.","journal-title":"Int J Colorectal Dis"},{"key":"847_CR12","doi-asserted-by":"publisher","first-page":"4518","DOI":"10.3390\/jcm11154518","volume":"11","author":"M Chaparro","year":"2022","unstructured":"Chaparro M, Baston-Rey I, Fern\u00e1ndez Salgado E, Gonz\u00e1lez Garc\u00eda J, Ramos L, Diz-Lois Palomares MT, et al. Using interpretable machine learning to identify baseline predictive factors of remission and drug durability in Crohn\u2019s disease patients on ustekinumab. J Clin Med. 2022;11:4518.","journal-title":"J Clin Med"},{"key":"847_CR13","doi-asserted-by":"publisher","first-page":"9181","DOI":"10.2147\/JIR.S479618","volume":"17","author":"T Su","year":"2024","unstructured":"Su T, Liu L, Meng F, Wu H, Liu T, Deng J, et al. Prediction of the short-term effectiveness of ustekinumab in patients with moderate to severe Crohn\u2019s disease. J Inflamm Res. 2024;17:9181\u201391.","journal-title":"J Inflamm Res"},{"key":"847_CR14","doi-asserted-by":"publisher","first-page":"3440","DOI":"10.3748\/wjg.v27.i24.3440","volume":"27","author":"A Aksan","year":"2021","unstructured":"Aksan A, Farrag K, Blumenstein I, Schr\u00f6der O, Dignass AU, Stein J. Chronic intestinal failure and short bowel syndrome in Crohn\u2019s disease. World J Gastroenterol. 2021;27:3440\u201365.","journal-title":"World J Gastroenterol"},{"key":"847_CR15","unstructured":"European Medical Agency, Annex I. Summary of Product Characteristics (STELARA) [Internet]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/stelara-epar-product-information_en.pdf"},{"key":"847_CR16","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1136\/gut.2005.082909","volume":"55","author":"J Satsangi","year":"2006","unstructured":"Satsangi J. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006;55:749\u201353.","journal-title":"Gut"},{"key":"847_CR17","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/S0140-6736(80)92767-1","volume":"1","author":"RF Harvey","year":"1980","unstructured":"Harvey RF, Bradshaw JM. A simple index of Crohn\u2019s-disease activity. Lancet. 1980;1:514.","journal-title":"Lancet"},{"key":"847_CR18","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/S0016-5107(04)01878-4","volume":"60","author":"M Daperno","year":"2004","unstructured":"Daperno M, D\u2019Haens G, Van Assche G, Baert F, Bulois P, Maunoury V, et al. Development and validation of a new, simplified endoscopic activity score for Crohn\u2019s disease: the SES-CD. Gastrointest Endosc. 2004;60:505\u201312.","journal-title":"Gastrointest Endosc"},{"key":"847_CR19","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1093\/ibd\/izac130","volume":"29","author":"N Narula","year":"2023","unstructured":"Narula N, Wong ECL, Dulai PS, Marshall JK, Jairath V, Reinisch W. The performance of the rutgeerts score, SES-CD, and MM-SES-CD for prediction of postoperative clinical recurrence in Crohn\u2019s disease. Inflamm Bowel Dis. 2023;29:716\u201325.","journal-title":"Inflamm Bowel Dis"},{"key":"847_CR20","first-page":"537","volume":"72","author":"A Miranda","year":"2021","unstructured":"Miranda A, Gravina AG, Cuomo A, Mucherino C, Sgambato D, Facchiano A, et al. Efficacy of ustekinumab in the treatment of patients with Crohn\u2019s disease with failure to previous conventional or biologic therapy: a prospective observational real-life study. J Physiol Pharmacol. 2021;72:537\u201343.","journal-title":"J Physiol Pharmacol"},{"key":"847_CR21","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1080\/14712598.2020.1707800","volume":"20","author":"FS Macaluso","year":"2020","unstructured":"Macaluso FS, Maida M, Ventimiglia M, Cottone M, Orlando A. Effectiveness and safety of Ustekinumab for the treatment of Crohn\u2019s disease in real-life experiences: a meta-analysis of observational studies. Expert Opin Biol Ther. 2020;20:193\u2013203.","journal-title":"Expert Opin Biol Ther"},{"key":"847_CR22","first-page":"CD008870","volume":"7","author":"WC Lim","year":"2016","unstructured":"Lim WC, Wang Y, MacDonald JK, Hanauer S. Aminosalicylates for induction of remission or response in Crohn\u2019s disease. Cochrane Database Syst Rev. 2016;7:CD008870.","journal-title":"Cochrane Database Syst Rev"},{"key":"847_CR23","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.ijsu.2014.02.010","volume":"12","author":"Z Yang","year":"2014","unstructured":"Yang Z, Ye X, Wu Q, Wu K, Fan D. A network meta-analysis on the efficacy of 5-aminosalicylates, immunomodulators and biologics for the prevention of postoperative recurrence in Crohn\u2019s disease. Int J Surg. 2014;12:516\u201322.","journal-title":"Int J Surg"},{"key":"847_CR24","first-page":"CD008414","volume":"1","author":"M Gordon","year":"2011","unstructured":"Gordon M, Naidoo K, Thomas AG, Akobeng AK. Oral 5-aminosalicylic acid for maintenance of surgically-induced remission in Crohn\u2019s disease. Cochrane Database Syst Rev. 2011;1:CD008414.","journal-title":"Cochrane Database Syst Rev"},{"key":"847_CR25","doi-asserted-by":"publisher","first-page":"102090","DOI":"10.1016\/j.clinre.2023.102090","volume":"47","author":"L Zhang","year":"2023","unstructured":"Zhang L, Hu C, Zhang Z, Liu R, Liu G, Xue D, et al. Association between prior appendectomy and the risk and course of Crohn\u2019s disease: a systematic review and meta-analysis. Clin Res Hepatol Gastroenterol. 2023;47:102090.","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"847_CR26","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1097\/00042737-200506000-00006","volume":"17","author":"G Riegler","year":"2005","unstructured":"Riegler G, Caserta L, Esposito I, De Filippo FR, Bossa F, Esposito P, et al. Worse clinical course of disease in Crohn\u2019s patients with previous appendectomy. Eur J Gastroenterol Hepatol. 2005;17:623\u20137.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"847_CR27","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.3748\/wjg.v12.i8.1235","volume":"12","author":"J Cosnes","year":"2006","unstructured":"Cosnes J, Seksik P, Nion-Larmurier I, Beaugerie L, Gendre JP. Prior appendectomy and the phenotype and course of Crohn\u2019s disease. World J Gastroenterol. 2006;12:1235\u201342.","journal-title":"World J Gastroenterol"},{"key":"847_CR28","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1093\/ibd\/izae059","volume":"31","author":"A Mark-Christensen","year":"2025","unstructured":"Mark-Christensen A, Kristiansen EB, Laurberg S, Erichsen R. Prior appendectomy is associated with a milder clinical course in Crohn\u2019s disease: a nationwide population-based cohort study. Inflamm Bowel Dis. 2025;31:123\u201330.","journal-title":"Inflamm Bowel Dis"},{"key":"847_CR29","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.jcol.2017.12.004","volume":"39","author":"ACCF Loureiro","year":"2019","unstructured":"Loureiro ACCF, Barbosa LER. Appendectomy and Crohn\u2019s disease. J Coloproctol. 2019;39:373\u201380.","journal-title":"J Coloproctol"},{"key":"847_CR30","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.disamonth.2017.07.001","volume":"64","author":"M Gajendran","year":"2018","unstructured":"Gajendran M, Loganathan P, Catinella AP, Hashash JG. A comprehensive review and update on Crohn\u2019s disease. Dis Mon. 2018;64:20\u201357.","journal-title":"Dis Mon"},{"key":"847_CR31","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1053\/gast.1996.v111.pm8780560","volume":"111","author":"JM Polito","year":"1996","unstructured":"Polito JM, Childs B, Mellits ED, Tokayer AZ, Harris ML, Bayless TM. Crohn\u2019s disease: influence of age at diagnosis on site and clinical type of disease. Gastroenterology. 1996;111:580\u20136.","journal-title":"Gastroenterology"},{"key":"847_CR32","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1093\/ecco-jcc\/jjw168","volume":"11","author":"F Gomoll\u00f3n","year":"2017","unstructured":"Gomoll\u00f3n F, Dignass A, Annese V, Tilg H, Van Assche G, Lindsay JO, et al. ECCO. 3rd European evidence-based consensus on the diagnosis and management of Crohn\u2019s disease 2016: Part 1: Diagnosis and Medical Management. J Crohns Colitis. 2017;11:3\u201325.","journal-title":"J Crohns Colitis"},{"key":"847_CR33","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1111\/jgh.16562","volume":"39","author":"CT Lim","year":"2024","unstructured":"Lim CT, Tay SW, Elangovan S, Ong WC, Lim GH, Salazar E, et al. Long-term effectiveness and persistence rate of ustekinumab dose intensification in a South East Asian inflammatory bowel disease center. J Gastroenterol Hepatol. 2024;39:1544\u201353.","journal-title":"J Gastroenterol Hepatol"},{"key":"847_CR34","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1097\/MEG.0000000000002506","volume":"35","author":"PWA Thomas","year":"2023","unstructured":"Thomas PWA, van Caem M, West RL, Russel MGVM, Jansen JM, R\u00f6mkens TEH, Hoentjen F. IBDREAM registry. Long-term effectiveness and safety of ustekinumab in Crohn\u2019s disease: a prospective cohort study. Eur J Gastroenterol Hepatol. 2023;35:261\u20139.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"847_CR35","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.cgh.2020.02.035","volume":"19","author":"JE Ollech","year":"2021","unstructured":"Ollech JE, Normatov I, Peleg N, Wang J, Patel SA, Rai V, et al. Effectiveness of ustekinumab dose escalation in patients with Crohn\u2019s disease. Clin Gastroenterol Hepatol. 2021;19:104\u201310.","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["Pharmacological Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-026-00847-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43440-026-00847-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-026-00847-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T07:51:28Z","timestamp":1781682688000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43440-026-00847-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,24]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["847"],"URL":"https:\/\/doi.org\/10.1007\/s43440-026-00847-5","relation":{},"ISSN":["1734-1140","2299-5684"],"issn-type":[{"value":"1734-1140","type":"print"},{"value":"2299-5684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,24]]},"assertion":[{"value":"15 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No human experimentation was performed. The reference centre (Brotzu Hospital, Cagliari, Italy, protocol no. PG\/2020\/9414, dated 29 April 2020) obtained ethics committee approval for this retrospective study, which the other participating centres accepted. The study was performed in accordance with the 1964 Declaration of Helsinki and its amendments.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"was obtained from all patients at the time of enrolment. All procedures were executed in accordance with the 1964 Declaration of Helsinki and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"A.T. has served as a speaker and\/or consultant for AbbVie, Bayer, Fenix Pharma, Gal\u00e1pagos, Janssen, Nalkein, Omega Pharma, and SILA; R.P. has received sponsorship for participation in national and\/or international conferences from Pfizer Inc., Eli Lilly, Alfasigma, and Abbvie; G.M. has served as speaker for and\/or received advisory board fees from AbbVie, Amgen, Aurora Biopharma, Biogen, Celltrion, Chiesi, Fenix Pharma, Ferring, Gal\u00e1pagos, Janssen, MSD, Omega Pharma, Sandoz, Takeda, and Vifor Pharma; F.S. served as a lecturer for AbbVie, Celltrion, Ferring, Janssen, Lilly, Pfizer, Sanofi, and Takeda; E.V.S. has served as a speaker for AbbVie, AGPharma, Alfasigma, Dr Falk, EG Stada Group, Fresenius Kabi, Grifols, Janssen, Innovamedica, Malesci, Pfizer, Reckitt Benckiser, Sandoz, SILA, Sofar, Takeda, and Unifarco and has served as consultant for Alfasigma, Amgen, Biogen, Bristol-Myers Squibb, Celltrion, Diadema Farmaceutici, Dr Falk, Fresenius Kabi, Janssen, Merck & Co., Reckitt Benckiser, Regeneron, Sanofi, Shire, SILA, Sofar, Synformulas GmbH, Takeda, and Unifarco; he received research support from Pfizer, Reckitt Benckiser, SILA, Sofar, and Unifarco; G.M. has served as a speaker for and\/or has received advisory board fees from AlfaSigma, Arena, Janssen, Gilead, and Roche; A.P. received speaker fees from Alfasigma and Janssen; A.G.G. has conducted training activities [e.g. educational continuing medical activities (ECM), preceptorship] for Pfizer, Galapagos Biopharma, and AbbVie.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}